Bicara Therapeutics (BCAX) Cash from Financing Activities (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Cash from Financing Activities of $163.3 million for Q1 2026, up 35409.78% year-over-year from N/an in Q1 2025, and up 423.04% quarter-over-quarter from $31.2 million in Q4 2025.
Bicara Therapeutics (BCAX) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $163.3 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 35409.78% year-over-year to $163.3 million; the TTM figure through Mar 2026 stood at $195.1 million (down 41.63% YoY), while the FY2025 annual figure was $32.3 million, down 90.34% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $163.3 million, up from $31.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $334.1 million in Q3 2024, with the low at -$975000.0 in Q4 2024.
- The 4-year median for Cash from Financing Activities is $597000.0 (2024), against an average of $72.4 million.
- The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities slumped 100.5% in 2024, then jumped 35409.78% in 2026.
- Bicara Therapeutics' Cash from Financing Activities stood at $194.7 million in 2023, then plunged by 100.5% to -$975000.0 in 2024, then jumped by 3303.08% to $31.2 million in 2025, then surged by 423.04% to $163.3 million in 2026.
- Business Quant data shows BCAX's Cash from Financing Activities at $163.3 million in Q1 2026, $31.2 million in Q4 2025, and $436000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 2.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.33 Mn |
| Jun 30, 2026 | 2.33 Mn |
| Mar 31, 2026 | 163.35 Mn |
| Mar 31, 2026 | 163.35 Mn |
| Dec 31, 2025 | 31.23 Mn |
| Dec 31, 2025 | 31.23 Mn |
| Sep 30, 2025 | 436,000.00 |
| Sep 30, 2025 | 436,000.00 |
| Jun 30, 2025 | 135,000.00 |
| Jun 30, 2025 | 135,000.00 |
| Mar 31, 2025 | 460,000.00 |
| Mar 31, 2025 | 460,000.00 |
| Dec 31, 2024 | -975,000.00 |
| Dec 31, 2024 | -975,000.00 |
| Sep 30, 2024 | 334.14 Mn |
| Sep 30, 2024 | 334.14 Mn |
| Jun 30, 2024 | 734,000.00 |
| Jun 30, 2024 | 734,000.00 |
| Mar 31, 2024 | 137,000.00 |
| Mar 31, 2024 | 137,000.00 |